Positive neonatal screening is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multiple systemic strain. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat genetic metabolic diseases have been significantly improved. Treatment requires close monitoring of therapeutic effects and adverse reactions and timely adjustment to changes in the course of treatment.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of positive neonatal screening with carcinoma deficiency. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.